Jeevan Scientific Technology Ltd (JSTL) Announcements - Latest Exchange Filings with AI Summaries
Latest corporate announcements filed by Jeevan Scientific Technology Ltd on NSE and BSE, with an AI summary of each filing.
Jeevan Scientific Technology Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 11/11/2026 ,inter alia, to consider and approve Intimation of ....
Intimation · 11 Nov 2026, 5:30 am
Jeevan Scientific Technology Schedules Board Meeting for Q2 FY27 Results Jeevan Scientific Technology Limited announced that its Board of Directors will meet on 11th Nov'26 to consider and approve the standalone and consolidated unaudited financial results for the quarter and half-year ended 30th Sep'26. The board will also review the corresponding Limited Review Reports, pursuant to SEBI Listing Regulations.
Announcement under Regulation 30 of SEBI (LODR) Regulations, 2015
Others (Uncategorized) · 01 Oct 2026, 8:05 pm
Jeevan Scientific Receives US FDA EIR with Zero Observations for Hyderabad Facility Jeevan Scientific Technology Limited received the Establishment Inspection Report (EIR) from the US FDA on 30th Sep'26, concluding the inspection of its Bioanalytical Facility in Manikonda, Hyderabad. The regulatory audit, conducted between 20th Jul'26 and 24th Jul'26, closed successfully with zero Form 483 observations, marking full regulatory clearance under 21 CFR 20.64(d)(3).
Disclosure under Regulation 44(3) (Listing Obligations and Disclosure Requirements) Regulations, 2015.
Annual General Meeting · 25 Sept 2026, 6:06 pm
Jeevan Scientific Technology AGM Approves All Resolutions With Requisite Majority Jeevan Scientific Technology Limited announced the voting results of its 28th AGM held on 25th Sep'26. All eight resolutions were approved by shareholders with requisite majority. Approved items include the adoption of FY26 standalone and consolidated audited financial statements, the reappointment of rotational directors Krishna Kishore Kuchipudi and Snigdha Mothukuri, the reappointment of Snigdha Mothukuri as Whole Time Director, the continuation and reappointment of Nageswar Rao Yarllagadda as Whole Time Director beyond 70 years of age, and the appointments/reappointments of Independent Directors Suryaprakasa Rao Bommisetti and Kolli Srinivas Rao.
Outcome of 28th Annual General Meeting held on 25-09-2026
Annual General Meeting · 25 Sept 2026, 6:00 pm
28th Annual report
Others (Uncategorized) · 04 Sept 2026, 1:00 am
28th Annual General meeting of the Company is scheduled to be held on 25.09.2026 at 10:00 a.m.
Annual General Meeting · 04 Sept 2026, 12:55 am
Statement on Deviation or Variation of funds under Regulation 32 of SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015.
Others (Uncategorized) · 13 Aug 2026, 9:04 pm
Jeevan Scientific Reports No Deviation in Use of Preferential Allotment Funds Jeevan Scientific Technology Limited confirms no deviation in the utilization of funds from its preferential equity allotment for the quarter ended 30 Jun '26. The company raised ₹30.74 crore on 02 Jan '26. As of the quarter-end, ₹14.84 crore has been utilized, primarily for capital expenditure (₹4.14 crore), subsidiary working capital/capex (₹3.01 crore), and acquisitions (₹3.00 crore). All funds were used in line with the originally stated objectives, with no modifications or variations reported.
Announcement under Regulation 30 (LODR)- change in management
Change in Management · 13 Aug 2026, 8:45 pm
Jeevan Scientific Board Approves Q1FY27 Results and Key Appointments Jeevan Scientific Technology's board approved Q1FY27 results on 13 Aug'26. Standalone PAT stood at ₹188.60 lakhs, up from ₹159.48 lakhs QoQ and reversing a ₹215.99 lakh loss YoY. Consolidated PAT was ₹86.97 lakhs. The board approved several key re-appointments including Mrs. Snigdha Mothukuri and Mr. Nageswar Rao Yarllagadda as Whole Time Directors. Mr. Suryaprakasa Rao Bommisetti was re-appointed as an Independent Director. The FY26 AGM is scheduled for 25 Sep'26. A new Independent Director, Mr. Kolli Srinivas Rao, was also appointed.
Unaudited financial results (standalone and consolidated) for the quarter ended 30.06.2026.
Financial Result · 13 Aug 2026, 8:31 pm
Outcome of the Board Meeting held on 13.08.2026
Outcome · 13 Aug 2026, 8:26 pm
Jeevan Scientific Technology Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 13/08/2026 ,inter alia, to consider and approve Intimation of ....
Intimation · 13 Aug 2026, 5:30 am
Jeevan Scientific Technology Board to Review Q1 FY27 Results Jeevan Scientific Technology will hold a Board Meeting on 13th Aug'26 to consider and approve its unaudited standalone and consolidated financial results for the quarter ended 30th Jun'26. The agenda also includes approving the limited review report for the same period. Additionally, the board will finalize the date, time, and venue for the 28th Annual General Meeting for FY26 and approve the corresponding Directors' Report and AGM notice.
Intimation of Approval for addition of Beds to the Existing Approved Bioavailability/ Bioequivalence Center of Jeevan Scientific Technology Limited''s Bioavailability/ Bioequivalence Study ....
Others (Uncategorized) · 02 Aug 2026, 12:27 am
Jeevan Scientific Gets CDSCO Nod for Bed Capacity Expansion Jeevan Scientific Technology received approval from the CDSCO on 01 Aug'26 to increase capacity at its Bioavailability/Bioequivalence (BA/BE) Study Center in Hyderabad. Total bed capacity will rise from 132 to 156 beds, while ICU beds will increase from 6 to 8. This enhancement, following a successful regulatory inspection on 24 Jun'26, strengthens the company's clinical research infrastructure and operational capabilities. The expansion is expected to enable a higher volume of BA/BE studies, supporting future business growth for the company.
Information about the Successful Completion of USFDA Inspection at JSTL under Regulation 30 of SEBI (LODR) Regulations, 2015.
Others (Uncategorized) · 24 Jul 2026, 5:47 pm
Jeevan Scientific's Hyderabad Facility Clears USFDA Inspection With Zero Observations Jeevan Scientific Technology's Bioanalytical Facility in Manikonda, Hyderabad successfully completed a US Food and Drug Administration (USFDA) inspection. The audit, conducted from 20th Jul'26 to 24th Jul'26, concluded with "No Observations" (Zero 483s). This is a significant positive regulatory outcome for the company, affirming its compliance with international standards for its BA/BE studies and operational procedures. The successful inspection de-risks a key facility and clears it for continued operations related to the US market.
Notification of Inspection for additional beds to the Existing Approved Bioavailability/ Bioequivalence center of Jeevan Scientific Technology.
Others (Uncategorized) · 25 Jun 2026, 9:28 pm
Jeevan Scientific Announces Successful CDSCO Inspection for Facility Expansion Jeevan Scientific Technology successfully completed an inspection by the Central Drugs Standard Control Organization (CDSCO) on 24 Jun'26 at its Bioavailability/Bioequivalence (BA/BE) Study Centre in Hyderabad. The inspection was conducted to approve the addition of beds to the existing facility. Successful completion is a positive regulatory step, clearing the way for potential capacity expansion at the key study center. This development supports the company's growth plans and operational scale-up for conducting BA/BE studies.
Statement of Deviation or Variation of funds under Regulation 32 of SEBI (Listing Obligations and Disclosure Requirement) Regulations, 2015.
Others (Uncategorized) · 29 May 2026, 11:21 pm
Jeevan Scientific Technology: No Deviation in Preferential Allotment Fund Utilization Jeevan Scientific Technology reported no deviation or variation in utilizing funds from its preferential allotment for the quarter ended 31 Mar'26. The company raised ₹3074 Lakhs on 02 Jan'26 through an equity issue. As of 31 Mar'26, funds utilized include ₹365.73 Lakhs for capital expenditure, ₹300.00 Lakhs for acquisition of API/formulation units, ₹189.04 Lakhs for general corporate purposes, and ₹229.23 Lakhs for working capital requirements and subsidiary support. No modifications were made to the original allocation objectives.
Appointment of M/s. KP & Associates, Chartered Accountants as Internal Auditors of the Company for the FY 2026-27
Change in Management · 29 May 2026, 8:06 pm
Jeevan Scientific Board Approves FY26 Results, ESOP Grant, and Allotment Jeevan Scientific Technology's board approved audited financial results for Q4 and FY ended 31 Mar'26. For FY26, consolidated PAT stood at ₹103.33 lakh on revenue of ₹6,153.71 lakh, compared to ₹5.90 lakh PAT and ₹4,684.36 lakh revenue YoY. The board also granted 4,80,000 new stock options and allotted 1,61,250 equity shares at ₹10/- each upon the exercise of existing ESOPs. Additionally, KP & Associates were appointed as Internal Auditors for FY27. The statutory auditors provided an unmodified opinion on the financials.
Audited financial results for the quarter and year ended 31.03.2026
Financial Result · 29 May 2026, 7:58 pm
Jeevan Scientific Q4FY26 PAT Rises to ₹1.84 cr, Revenue Jumps 112% YoY Jeevan Scientific Technology reported a consolidated net profit of ₹1.84 cr for Q4FY26, against a loss of ₹1.26 cr in Q4FY25. Revenue from operations more than doubled to ₹21.29 cr, a 112% YoY increase. For the full year FY26, net profit surged to ₹1.03 cr from ₹0.06 cr in FY25, while revenue grew 31.4% YoY to ₹61.54 cr. The Board approved these audited results on 29 May'26. Basic EPS for Q4FY26 stood at ₹0.92, compared to ₹(0.81) last year.
Outcome of Board Meeting held on 29.05.2026
Outcome · 29 May 2026, 7:49 pm
Jeevan Scientific Technology Ltd - Financial Result for the Quarter ended 31st Mar'26 (Consolidated, INR Lakhs) ■ Revenue: 2,129 (+111.6% YoY | +11.6% QoQ) ■ EBITDA: 430 (Loss to Profit YoY | -17.7% QoQ) ■ EBITDA Margin (%): 20.2 (Loss to Profit YoY | -720 bps QoQ) ■ PAT: 161 (Loss to Profit YoY | +13.0% QoQ) ■ EPS (INR): 1.09 (Loss to Profit YoY | -28.3% QoQ)
Jeevan Scientific Technology Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 29/05/2026 ,inter alia, to consider and approve Intimation of ....
Intimation · 29 May 2026, 5:30 am
Jeevan Scientific Technology Schedules Board Meeting for Q4 and FY26 Results Jeevan Scientific Technology Ltd. has scheduled a Board of Directors meeting for May 29, '26. The primary agenda is to consider and approve the audited standalone and consolidated financial statements for the fourth quarter and the full financial year ended Mar 31, '26. This meeting is crucial for the release of the company's Q4 and annual earnings, which will provide key insights into its financial performance and operational health. Any other business will also be considered with the Chair's permission.
<b>Format of the Annual Disclosure to be made by an entity identified as a Large Corporate.</b><br/><br/> <table border=''1px''> <tr> <td><b>Sr. No.</b></td> <td><b>Particulars</b></td> ....
Others (Uncategorized) · 01 May 2026, 12:21 am
Jeevan Scientific Technology Confirms It Is Not a Large Corporate Jeevan Scientific Technology Limited informed exchanges on 29 Apr'26 that it does not qualify as a Large Corporate (LC) under the SEBI framework for FY26. Consequently, the mandatory requirement to raise 25% of incremental borrowings through debt securities is not applicable to the company. The annual disclosure confirms that for the two-year block period of FY26-FY27, there is no mandatory borrowing obligation, actual debt issuance, or shortfall, as the regulations do not apply. This status exempts the company from potential penalties related to debt fundraising rules.
<b>Format of Initial Disclosure to be made by an entity identified as a Large Corporate.</b><br/><br/> <table border=''1px''><tr> <td><b>Sr. No.</b></td> <td><b>Particulars</b></td> <td><b>Details</b></td> ....
Others (Uncategorized) · 01 May 2026, 12:14 am
Jeevan Scientific Technology Does Not Qualify as a "Large Corporate" for FY27 Jeevan Scientific Technology Limited announced on 29 Apr'26 that it does not qualify as a "Large Corporate" under SEBI's framework for FY 2026-2027. The company only meets one of the three required criteria (having listed equity shares). It fails to meet the thresholds for outstanding long-term borrowings of ₹1,000 crore or more and a credit rating of "AA" or higher. As of 31 Mar'26, the company's outstanding borrowing was ₹11.58 crore. Therefore, the requirement for initial disclosure as a Large Corporate is not applicable.
<b>Format of the Annual Disclosure to be made by an entity identified as a Large Corporate.</b><br/><br/> <table border=''1px''> <tr> <td><b>Sr. No.</b></td> <td><b>Particulars</b></td> ....
Others (Uncategorized) · 30 Apr 2026, 11:19 pm
Jeevan Scientific Clarifies It Is Not a "Large Corporate" Jeevan Scientific Technology Limited informed exchanges on 29 Apr'26 that it does not fall under the "Large Corporate" (LC) category as per the SEBI circular dated 19 Oct'23. Consequently, the mandatory requirement to raise a portion of its incremental borrowings via debt securities is not applicable to the company for the FY25-26 reporting period. This disclosure clarifies the company's status regarding specific SEBI fundraising regulations.
<b>Format of Initial Disclosure to be made by an entity identified as a Large Corporate.</b><br/><br/> <table border=''1px''><tr> <td><b>Sr. No.</b></td> <td><b>Particulars</b></td> <td><b>Details</b></td> ....
Others (Uncategorized) · 30 Apr 2026, 11:13 pm
Jeevan Scientific Technology Does Not Qualify as a Large Corporate for FY27 Jeevan Scientific Technology Limited announced on 29-Apr'26 that it does not qualify as a "Large Corporate" for FY27 under SEBI's framework. The company meets only one of the three required criteria (being listed), but fails to meet the other two: outstanding long-term borrowings of ₹1,000 crore or more, and a credit rating of "AA" or higher. As of 31-Mar'26, its outstanding borrowing was ₹11.58 crore. Consequently, the company is not subject to the mandatory initial disclosure requirements for Large Corporates.
The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Nageswar Rao Yarlagadda
Acquisition/ Disposal of Shares · 30 Mar 2026, 11:34 pm
Jeevan Scientific Director Sells Stake in Off-Market Deal Nageswar Rao Yarlagadda, an Executive Director at Jeevan Scientific Technology Limited, sold 100,000 equity shares in an off-market transaction on 27 Mar'26. This disposal reduced his shareholding from 133,900 shares (0.67% of total capital) to 33,900 shares (0.17%). The transaction represents a sale of 0.50% of the company's total voting capital. The seller does not belong to the Promoter group. This disclosure was filed under SEBI's substantial acquisition regulations.
The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Nageswar Rao Yarlagadda
Acquisition/ Disposal of Shares · 30 Mar 2026, 11:10 pm
Executive Director Sells Stake in Jeevan Scientific Technology Nageswar Rao Yarlagadda, an Executive Director at Jeevan Scientific Technology, sold 1,00,000 equity shares via an off-market transaction on 27-Mar'26. This disposal represents 0.50% of the company's total share capital. Following the sale, his shareholding has been reduced from 1,33,900 shares (0.67% stake) to 33,900 shares (0.17% stake). The filing confirms the seller is not part of the promoter group.